Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database.
作者信息
Salem Riad, Gabr Ahmed
机构信息
Department of Interventional Radiology, Northwestern University, Chicago, Illinois
Department of Interventional Radiology, Northwestern University, Chicago, Illinois.
出版信息
J Nucl Med. 2022 Jan;63(1):57-58. doi: 10.2967/jnumed.121.262917. Epub 2021 Dec 16.
Abstract
摘要
相似文献
1
Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database.
J Nucl Med. 2022 Jan;63(1):57-58. doi: 10.2967/jnumed.121.262917. Epub 2021 Dec 16.
2
Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
Clin Liver Dis. 2014 Nov;18(4):877-90. doi: 10.1016/j.cld.2014.07.007. Epub 2014 Aug 22.
3
Ruptured Hepatocellular Carcinoma following Transarterial Radioembolization.
J Vasc Interv Radiol. 2018 Sep;29(9):1302-1305. doi: 10.1016/j.jvir.2018.04.017.
4
Transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion: a helpful palliative approach.
J Gastroenterol Hepatol. 2009 Aug;24(8):1317-9. doi: 10.1111/j.1440-1746.2009.05976.x.
5
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24.
6
Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
J Gastroenterol Hepatol. 2014 Nov;29(11):1897-904. doi: 10.1111/jgh.12621.
7
Ablative Transarterial Radioembolization of a Parasitized Adrenal Artery for the Treatment of Hepatocellular Carcinoma.
J Vasc Interv Radiol. 2019 Mar;30(3):473-476. doi: 10.1016/j.jvir.2018.10.022.
8
Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-Year Experience.
J Vasc Interv Radiol. 2018 Jul;29(7):912-919.e2. doi: 10.1016/j.jvir.2018.03.018. Epub 2018 May 26.
9
Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization.
Diagn Interv Imaging. 2019 Nov;100(11):689-697. doi: 10.1016/j.diii.2019.05.006. Epub 2019 Jul 4.
10
Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
J Hepatol. 2018 Apr;68(4):724-732. doi: 10.1016/j.jhep.2017.12.026. Epub 2018 Jan 10.
引用本文的文献
1
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.
Eur J Radiol Open. 2023 Jan 31;10:100477. doi: 10.1016/j.ejro.2023.100477. eCollection 2023.
本文引用的文献
1
Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: Analysis of the US National Cancer Database.
J Nucl Med. 2021 Apr 9;62(12):1692-701. doi: 10.2967/jnumed.121.261954.
2
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Hepatology. 2021 Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11.
3
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28.
4
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7.
5
Observing Durable Responses and a Prolonged Survival Tail in Advanced Hepatocellular Carcinoma with Portal Vein Invasion Treated with Y90 Radioembolization.
Cardiovasc Intervent Radiol. 2020 Sep;43(9):1423-1424. doi: 10.1007/s00270-020-02541-2. Epub 2020 Jun 3.
6
Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Hepatology. 2021 Mar;73(3):998-1010. doi: 10.1002/hep.31318. Epub 2020 Nov 7.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Cardiovasc Intervent Radiol. 2018 Oct;41(10):1557-1565. doi: 10.1007/s00270-018-2008-y. Epub 2018 Jun 12.
9
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.
10
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
Zotero 插件